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Objectives: Some patients are medically unﬁt for or averse to undergoing a brachytherapy
boost as part of cervical cancer radiotherapy. In order to be able to deﬁnitively treat these
patients, we assessed whether we could achieve a boost plan that would mimic our
brachytherapy plans using external beam radiotherapy.
Methods: High dose rate brachytherapy plans of 20 patients with stage IIB cervical cancer
treated with deﬁnitive chemoradiotherapy were included in this study. Patients had under-
gone computer tomography (CT) simulations with tandem and ovoids in place. Point “A”
dose was 600–700 cGy. We attempted to replicate the boost dose distribution from
brachytherapy plans using intensity-modulated radiotherapy (Varian Medical Systems, Palo
Alto, CA, USA), volumetric modulated arc therapy (Rapid Arc, Varian Medical Systems, Palo
Alto, CA, USA), orTomoTherapy (Accuray, Inc., Sunnyvale, CA, USA) with the brachytherapy
100% isodose line as our target. Target coverage, normal tissue dose, and brachytherapy
point doses were compared with ANOVA. Two-sided p-values ≤0.05 were considered
signiﬁcant.
Results: External beam plans had excellent planning target volume (PTV) coverage, with
no difference in mean PTV V95% among planning techniques (range 98–100%). External
beam plans had lower bladder Dmax, small intestine Dmax, and vaginal mucosal point dose
than brachytherapy plans, with no difference in bladder point dose, mean bladder dose,
mean small intestine dose, or rectal dose. Femoral head dose, parametria point dose, and
pelvic sidewall point dose were higher with external beam techniques than brachytherapy.
Conclusions: External beam plans had comparable target coverage and potential for
improved sparing of most normal tissues compared to tandem and ovoid brachytherapy.
Keywords: cervical cancer, brachytherapy, external beam radiotherapy
INTRODUCTION
Localized cervical cancer (stage IB to IVA) is traditionally treated
with concurrent chemoradiotherapy. Radiotherapy is usually
administered through a three-dimensional conformal external
beam approach to bring the whole pelvis to a minimum dose of
45 Gy, followed by a brachytherapy boost to give additional dose to
the gross tumor within the cervix and parametria. This technique
is often successful, with 5-year survival rates ranging from 60 to
70% (Rose et al., 1999; Pearcey et al., 2002; Eifel et al., 2004).
High dose rate (HDR) brachytherapy is commonly admin-
istered with a tandem and ovoid applicator. There are several
beneﬁts of tandem and ovoid brachytherapy. It allows delivery
of a high radiation dose to the tumor site with rapid fall-off to
protect normal tissue. In addition, organ motion is less concern-
ing with an apparatus that is secured within target tissues of the
pelvis. However, there are several downsides to the procedure. It
is invasive, often requiring spinal or general anesthesia and con-
ferring operative risks such as uterine perforation, infection, and
bleeding. The tandem and ovoid apparatus is left in place for many
hours and can be painful without strong sedative and narcotic
medication.
Moderate to severe late complications of HDR brachytherapy
are common. Although a recent meta-analysis reported the rates
of moderate to severe late rectal or genitourinary toxicity to be 3%
or less, some series have shown moderate or severe late toxicity
rates of up to 23% for the rectum, 3% for the bladder, 6% for
the small bowel, and 30% for the vagina (Clark et al., 1994; Pötter
et al., 2000; Wang et al., 2010).
In light of the above risks, we questioned whether an external
beam brachytherapy boost is achievable for patients undergoing
deﬁnitive cervical cancer radiotherapy who are either medically
unﬁt for or refuse a brachytherapy boost. Speciﬁcally, using exter-
nal beam techniques, we tried to attain a similar dose distribution
with comparable or improved normal-tissue sparing to that seen
in previously treated brachytherapy plans at our institution.
Prior studies have evaluated the ability of external beam tech-
niques to mimic brachytherapy plans; however, these studies
included fewer patients and used only a single external beam tech-
nique (Wahab et al., 2004; Hsieh et al., 2010; Cengiz et al., 2012;
Haas et al., 2012). We focused on a cohort of 20 patients and
analyzed both volumetric and classical point dose endpoints to
compare and contrast previously treated brachytherapy plans with
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three external beam techniques: volumetric modulated arc ther-
apy (VMAT, Rapid Arc, Varian Medical Systems, Palo Alto, CA,
USA), intensity-modulated radiotherapy (IMRT, Varian Medical
Systems, Palo Alto, CA, USA), and TomoTherapy (Accuray, Inc.,
Sunnyvale, CA, USA).
MATERIALS AND METHODS
This study was approved by the institutional review board. Twenty
consecutive adult patients with a diagnosis of stage IIB cervical
cancer treated with deﬁnitive chemoradiotherapy between 2003
and 2010 were included. All patients had received external beam
radiotherapy to the whole pelvis followed by a tandem and ovoid
HDR brachytherapy boost. Patients had undergone computer
tomography (CT) simulation with tandem and ovoids in place
prior to boost delivery. For each patient, we attempted to replicate
the boost dose distribution from one of these planning CT scans
using IMRT, VMAT, or TomoTherapy.
Doses of 600–700 cGy had been previously prescribed for
each HDR brachytherapy fraction. The 100% prescription iso-
dose volume from the tandem and ovoid procedure was used as
the planning target volume (PTV) for external beam plans.
Normal tissues, including bladder, rectum, small intestine, and
femoral heads, were contoured by the same physician (Rajni A.
Sethi) on the planningCT scan and reviewed by a second physician
(Peter B. Schiff). An IMRT plan using up to 11 non-coplanar
beams was planned for 20 patients. A VMAT plan with two or
three 270◦ arcs and a TomoTherapy plan were created for 10 of
the study patients. Table 1 presents the dose constraints used for
the optimization of the external beam plans.
The following dosimetric parameters were recorded: volume of
PTV receiving 95% of the prescribed dose (V95), maximum dose
to the PTV, and maximum and mean doses to the bladder, rec-
tum, small intestine, and right and left femoral heads. In addition,
point doses to brachytherapy points A, points B, points P, vaginal
mucosal point, bladder point, and rectal point were also recorded.
The points were deﬁned according to ICRU 38 (International
Commission on Radiation Units and Measurements, 1985). The
bladder point is deﬁned on a lateral radiograph at the posterior
surface of the balloon along an anteroposterior line drawn through
the center of the Foley catheter balloon, and at the center of
Table 1 | Dose constraints used for intensity-modulated radiotherapy
and volumetric arc radiotherapy plans.
Structure Type Volume (%) Dose (cGy)
PTV Upper 0 1000
PTV Lower 100 710
Bladder Upper 0 400
Bladder Upper 3 300
Body Upper 3 400
Femoral head Upper 0 200
Rectum Upper 0 300
Small intestine Upper 0 200
PTV = planning target volume
the balloon on an anterior/posterior (AP) radiograph. The rectal
reference point is located, on a lateral radiograph, 5 mm behind
the posterior vaginal wall at the level of the inferior end of the
intrauterine. The pelvic sidewall reference point is located, on an
AP radiograph, at the intersection of orthogonal lines drawn tan-
gent to the highest and inner-most aspects of the acetabulum. On
a lateral radiograph, it is at the level of themidpoint of a line drawn
between the superior aspects of the right and left acetabula. Point
A was deﬁned on an AP radiograph 2 cm lateral to the plane of
tandem and 2 cm superior to the cervical. Point B is located at the
same level as Point A, 5 cm lateral from midline.
Because the prescribeddose for eachbrachytherapyplan ranged
from 600 to 700 cGy, all dosimetric values were normalized to
the prescription dose prior to statistical analysis and are pre-
sented as such in the results section. Single-factor ANOVA was
used to test for differences in dose to the PTV, normal structures,
or brachytherapy points among the four planning techniques. A
two-tailed t-test was then used to test for differences between
pairs of planning techniques for any parameters with signiﬁcant
differences on ANOVA. A two-sided p-value of 0.05 or less was
considered signiﬁcant for all statistical analyses.
RESULTS
DOSE TO TARGET VOLUME
Dose distributions among the three planning techniques for a rep-
resentative patient are shown in Figure 1. There was no difference
in point A dose, either right or left, among the planning tech-
niques, with a range of 97–102% of the prescription dose for all
plans (p = 0.23 for left point A, and p = 0.20 for right point A,
single-factor ANOVA). All plans had excellent PTV coverage when
the PTV was deﬁned as the treatment volume (within the 100%
isodose curve) on the tandem and ovoid plan. Mean PTV V95 was
98% for IMRT and 100% forVMAT and TomoTherapy plans. The
average maximum dose to the PTV was 112, 157, and 123% for
IMRT, VMAT, and TomoTherapy plans, respectively (p < 0.001,
two-tailed t-test).
DOSE TO NORMAL STRUCTURES
Results of volumetric analyses of dose to normal tissues and anal-
yses of brachytherapy point doses are presented in Table 2. Table 3
shows the results of pair-wise comparisons of techniques for any of
the parameters thatwere signiﬁcantly different byANOVAanalysis.
Target coverage was excellent with all three external beam
plans. There was no difference in average PTV-V95% among the
three external beam techniques: 98% for IMRT, 100% for VMAT,
and 100% for tandem and ovoid plans (p = 0.122, single-factor
ANOVA). PTV Dmax was signiﬁcantly higher for VMAT com-
pared to IMRT or TomoTherapy, averaging 157, 112, and 123%,
respectively (p < 0.001, single-factor ANOVA).
Tomotherapy had higher dose to point A than other planning
techniques. All three external beam techniques had higher point B
and point P doses than tandem and ovoid plans.
The maximum dose to the bladder was lower with exter-
nal beam plans compared to brachytherapy plans. IMRT and
TomoTherapy achieved the lowest bladder Dmax. There was no
difference in bladder mean dose or dose to the bladder point
among planning techniques.
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FIGURE 1 | Axial, sagittal, and coronal views of dose distribution among tandem and ovoid, intensity-modulated radiotherapy, volumetric modulated
arc therapy, andTomoTherapy techniques for a representative patient.
Table 2 | Comparison of dose to normal tissues and brachytherapy points, normalized to the prescription dose, among tandem and ovoid,
intensity-modulated radiotherapy, and volumetric arc radiotherapy techniques.
Mean (standard deviation)
IMRT T&O VMAT Tomotherapy p-value*
Rectum maximum dose 0.59 (0.14) 0.61 (0.25) 0.57 (0.09) 0.62 (0.11) 0.887
Rectum mean dose 0.20 (0.05) 0.23 (0.09) 0.19 (0.03) 0.23 (0.05) 0.280
Bladder maximum dose 0.98 (0.12) 1.47 (0.65) 1.15 (0.15) 1.03 (0.20) 0.002
Bladder mean dose 0.38 (0.09) 0.39 (0.09) 0.41 (0.06) 0.38 (0.05) 0.827
Small intestine maximum dose 1.00 (0.12) 1.30 (0.49) 1.01 (0.27) 1.01 (0.20) 0.019
Small intestine mean dose 0.22 (0.21) 0.21 (0.07) 0.15 (0.06) 0.19 (0.10) 0.553
Right femur maximum dose 0.31 (0.09) 0.12 (0.06) 0.35 (0.09) 0.34 (0.06) <0.001
Right femur mean dose 0.08 (0.03) 0.05 (0.03) 0.12 (0.07) 0.15 (0.11) <0.001
Left femur maximum dose 0.37 (0.10) 0.15 (0.07) 0.41 (0.10) 0.35 (0.09) <0.001
Left femur mean dose 0.09 (0.03) 0.07 (0.05) 0.15 (0.07) 0.19 (0.11) <0.001
Point A left 0.97 (0.03) 0.99 (0.06) 1.01 (0.08) 1.04 (0.07) 0.020
Point A right 0.98 (0.03) 0.98 (0.08) 1.02 (0.07) 1.05 (0.07) 0.031
Point B left 0.48 (0.13) 0.26 (0.04) 0.48 (0.13) 0.41 (0.04) <0.001
Point B right 0.38 (0.09) 0.25 (0.05) 0.41 (0.08) 0.39 (0.04) <0.001
Bladder point 0.56 (0.21) 0.62 (0.19) 0.57 (0.19) 0.54 (0.11) 0.727
Rectal point 0.49 (0.18) 0.47 (0.17) 0.49 (0.22) 0.51 (0.16) 0.938
Point P left 0.50 (0.14) 0.24 (0.07) 0.49 (0.13) 0.43 (0.06) <0.001
Point P right 0.38 (0.13) 0.20 (0.06) 0.47 (0.13) 0.38 (0.07) <0.001
Vaginal mucosal point left 1.03 (0.08) 1.44 (0.39) 0.99 (0.39) 1.08 (0.18) 0.001
Vaginal mucosal point right 1.03 (0.05) 1.37 (0.33) 0.99 (0.40) 1.07 (0.15) <0.001
*Single-factor ANOVA.
IMRT, intensity-modulated radiotherapy; T&O, tandem and ovoid; VMAT, volumetric arc radiotherapy.
Statistically signiﬁcant ANOVA values are represented in bold.
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Table 3 | Results of two-tailed t -tests for pair-wise comparisons of tandem and ovoid, intensity-modulated radiotherapy, volumetric modulated
arc therapy, andTomoTherapy techniques for dosimetric parameters and doses to brachytherapy points that showed statistically significant
differences on ANOVA analysis of normalized values.
T&O vs. IMRT T&O vs.VMAT T&O vs.Tomo IMRT vs.VMAT IMRT vs.Tomo VMAT vs.Tomo
Bladder Dmax 0.001 0.139 0.044 0.002 0.420 0.128
SI Dmax 0.005 0.100 0.031 0.899 0.933 0.974
R femur Dmax <0.001 <0.001 <0.001 0.217 0.334 0.550
R femur mean 0.037 0.002 0.001 0.078 0.011 0.027
L femur Dmax <0.001 <0.001 0.660 0.289 0.660 0.063
L femur mean 0.195 0.001 0.001 0.002 0.002 0.130
A left 0.293 0.432 0.059 0.051 0.001 0.441
A right 0.796 0.228 0.039 0.024 0.001 0.467
B left <0.001 <0.001 <0.001 0.980 0.137 0.092
B right <0.001 <0.001 <0.001 0.512 0.877 0.271
P left <0.001 <0.001 <0.001 0.828 0.126 0.301
P right <0.001 <0.001 <0.001 0.116 0.894 0.084
Mucosa right <0.001 0.019 0.007 0.698 0.340 0.313
Mucosa left <0.001 0.011 0.021 0.730 0.344 0.996
T&O, tandem and ovoid; IMRT, intensity-modulated radiotherapy; VMAT, volumetric arc radiotherapy; Tomo, TomoTherapy.
Statistically signiﬁcant ANOVA values are represented in bold.
Rectal point dose, maximum dose to the rectum, and
mean rectal dose were not different among the planning
techniques.
Small intestine maximum dose was lower with external beam
plans compared to brachytherapy plans, although no difference in
mean dose was found.
Vaginal mucosal point doses were lower with external beam
techniques compared to tandem and ovoid plans.
Femoral head mean and maximum doses were lower with
brachytherapy than with external beam techniques, with the
exception of left femur mean dose which was not on average dif-
ferent between IMRT and tandem and ovoid plans. Of the external
beam techniques, TomoTherapy incurred the highest femur mean
doses, and IMRT incurred the lowest femur mean doses.
DISCUSSION
We were able to obtain good coverage of the volume treated by
brachytherapy with improved normal tissue sparing with all three
external beam techniques. The most common sites of late com-
plications from tandem and ovoid brachytherapy are, in order of
decreasing incidence, vagina, rectum, small intestine, and blad-
der (Pötter et al., 2000; Chen et al., 2003; Wang et al., 2010). In
this study, IMRT, VMAT, and TomoTherapy enabled a reduc-
tion in vaginal mucosal dose as well as maximum dose to the
bladder and small intestine. IMRT and TomoTherapy were bet-
ter able to spare the bladder than VMAT, and TomoTherapy had
the highest femoral head doses. The external beam plans were
otherwise very similar. Because maximum dose to pelvic organs
has been correlated with late complication rates, use of an exter-
nal beam technique could theoretically result in fewer late tissue
effects (Petereit and Pearcey, 1999).
The dosimetric differences between the external beam plans
may be decreased or their quality improved by using different
optimization criteria for each modality. In this study we used the
same optimization criteria for a simpler comparison.
We used the prescription isodose curve from the tandem and
ovoid plan to deﬁne our PTV; however, an alternative method of
target deﬁnition would be required for clinical implementation
of an external beam boost, since tandem and ovoids will not be
in place. We anticipate using magnetic resonance imaging (MRI)
to assist with tumor and target deﬁnition, as several groups have
successfully done in clinical trials of image-guided brachytherapy
for locally advanced or recurrent cervical cancers (Fokdal et al.,
2011; Pötter et al., 2011).
Another consideration in planning an external beam boost is
the substantial organ motion and deformation displayed by the
pelvic organs, especially, the bladder, rectum, and uterus (Chan
et al., 2008; Lim et al., 2011). With brachytherapy, this motion
is overcome because the applicator is ﬁxed within the target tis-
sue. With an external beam technique, target motion becomes
an important concern, and internal target volume margins would
need to be deﬁned to allow for both organ motion and deforma-
tion during and between treatments. It is possible that, with the
addition of an internal target volume (ITV) expansion, dose to
organs at risk may be higher than what is represented here. How-
ever, with MRI-based planning to identify a gross tumor volume
(GTV), ﬁnal PTV volume, and corresponding dose to organs at
risk, may actually be lower than what is presented here. Finally,
image guidance and/or use of ﬁducial markers would be required
to account for inter-fraction motion.
A characteristic of brachytherapy is the rapid dose fall-off with
distance from the source. This means that, while the prescription
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point or volume receives the prescription dose, high risk tis-
sues near the source receive a substantially higher dose. In this
study, target coverage with the prescription dose was excellent
with external beam techniques; however, external beam tech-
niques do not capture the substantial dose inhomogeneity seen
with brachytherapy. We used a constraint to limit the maximum
dose in external beam plans, due to the uncertainty of hotspot
location, which could adversely impact a critical structure. The
question then arises as to the biological and clinical signiﬁcance of
this effect. There has been no correlation between HDR fraction
schedule or biologic equivalent dose with pelvic control or over-
all survival, for many common fractionation regimens (Petereit
and Pearcey, 1999). Also, there has been no proven beneﬁt of
high dose rate brachytherapy over low dose rate brachytherapy
in terms of pelvic control or survival (Wang et al., 2010). How-
ever, presently it is uncertain which dosimetric parameter, such
as minimum, average, or maximum tumor dose, is associated
with tumor control. Therefore, it is unclear whether our exter-
nal beam techniques, which maintained minimum tumor dose
but had a lower maximum dose, is biologically equivalent to
brachytherapy. Clinical implementation of an external beamboost
should accordingly be done in the setting of a prospective clinical
trial.
External beam techniques will expose more normal tissue
to low radiation doses through beam entry and exit paths, as
evidenced by the higher femoral head doses in external beam
plans in this study. Increased volume of tissue with low dose
exposure may incur a higher risk of second malignancy, which
could be a potential drawback of an external beam approach
(Hall and Wuu, 2003; Purdy, 2008). This issue is likely to be of
minimal importance in patients already receiving external beam
radiation.
The intended application of this technique is not to replace
brachytherapy as a modality, but rather as a tool for situations
when brachytherapy is not available. For example, patients who
are medically unﬁt for or refuse a brachytherapy procedure may
receive deﬁnitive treatment of their cancer. Radiation oncology
practices without brachytherapy expertise or equipment could
deﬁnitively treat their patients, which could particularly impact
patients in medically underserved areas. Although we mimic
an HDR brachytherapy dose schedule in this study, alternative
fractionation regimens, such as a daily concomitant boost or
stereotactic body radiotherapy, could be used within a research
setting to decrease total treatment time. This potentially could
lead to improved tumor control given prior evidence that overly
prolonged treatment schedules can negatively impact outcomes
(Lanciano et al., 1993; Chen et al., 2003).
In summary, external beam boost plans had good target cov-
erage with the prescription dose and had improved normal tissue
sparing compared to brachytherapy plans. Due to important con-
siderations such as target motion and target delineation, this
technique is limited in scope compared to traditional brachyther-
apy and should be clinically implemented in the setting of a
prospective feasibility trial.
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